. 2009 May;16(3):8–20. doi: 10.3747/co.v16i3.377

TABLE III.

Taxane/non-anthracycline regimen compared with single-agent taxane

Reference	Phase	Treatment arms	Pts (n)	Median pfs(months)	Medianttp(months)	Medianos(months)	orr(%)
O’Shaughnessy et al., 2002³⁴	iii	Docetaxel/capecitabine	255	nr	6.1^a	14.5^b	42^a
O’Shaughnessy et al., 2002³⁴	iii	Docetaxel	256	nr	4.2	11.5	30
Albain et al., 2004³⁵ (abstract)	iii	Paclitaxel/gemcitabine	267	nr	5.2^b	18.5^b	40.8
Albain et al., 2004³⁵ (abstract)	iii	Paclitaxel	262	nr	2.9	15.8	22.1
Beslija et al., 2006³⁸ (abstract)	ii	Docetaxel/capecitabine	50	nr	9.3^b	22	68^a
Beslija et al., 2006³⁸ (abstract)	ii	Docetaxel to capecitabine at progression	50	nr	7.7	19	40

^{^a}

p < 0.01.

^{^b}

p < 0.05.

Pts = patients; pfs = progression-free survival; ttp = time to progression; os = overall survival; orr = overall response rate; nr = not reported; 5-fu = 5-fluorouracil